| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $19,095,357 | 49 | 100 |
| Bjork Elisabeth | director | 0 | $0 | 1 | $293,166 | $-293,166 |
| Nijdam Anna | Principal Accounting Officer | 0 | $0 | 3 | $307,481 | $-307,481 |
| Nassif David W. | CFO / CLO | 0 | $0 | 2 | $521,877 | $-521,877 |
| Monges Viviane | director | 0 | $0 | 2 | $688,377 | $-688,377 |
| Glassman Robert | director | 0 | $0 | 3 | $930,358 | $-930,358 |
| Modig Berndt | Chief Executive Officer | 0 | $0 | 7 | $1.1M | $-1.1M |
| Souverijns Wim | Chief Commercial Officer | 0 | $0 | 3 | $1.32M | $-1.32M |
| Abele Stefan Andreas | Chief Technical Ops Officer | 0 | $0 | 2 | $2.03M | $-2.03M |
| Schikan Johannes Gerardus Christiaan Petrus | director | 0 | $0 | 8 | $2.65M | $-2.65M |
| Lu Peng | Chief Medical Officer | 0 | $0 | 10 | $3.45M | $-3.45M |
| Lesage Anne | Chief Early Development | 0 | $0 | 8 | $5.8M | $-5.8M |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE …
Over the last 12 months, insiders at Pharvaris N.V. have bought $0 and sold $19.1M worth of Pharvaris N.V. stock.
On average, over the past 5 years, insiders at Pharvaris N.V. have bought $0 and sold $19.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-09-23 | Sale | Monges Viviane | director | 11,969 0.0171% | $33.05 | $395,524 | -5.68% | |
| 2026-09-22 | Sale | Schikan Johannes Gerardus Christiaan Petrus | director | 800 0.0011% | $36.19 | $28,952 | -11.08% | |
| 2026-09-21 | Sale | Nassif David W. | CFO / CLO | 6,000 0.0086% | $36.47 | $218,801 | -12.80% | |
| 2026-09-15 | Sale | Abele Stefan Andreas | Chief Technical Ops Officer | 46,400 0.0666% | $38.17 | $1.77M | -16.76% | |
| 2026-09-15 | Sale | Souverijns Wim | Chief Commercial Officer | 6,090 0.0089% | $38.99 | $237,449 | -16.76% | |
| 2026-09-15 | Sale | Glassman Robert | director | 8,667 0.0125% | $38.27 | $331,716 | -16.76% | |
| 2026-09-14 | Sale | Modig Berndt | Chief Executive Officer | 2,291 0.0034% | $39.40 | $90,276 | -18.43% | |
| 2026-09-14 | Sale | Souverijns Wim | Chief Commercial Officer | 20,000 0.0297% | $39.31 | $786,126 | -18.43% | |
| 2026-09-11 | Sale | Lu Peng | President | 15,000 0.0233% | $40.13 | $601,947 | -16.57% | |
| 2026-09-10 | Sale | Lesage Anne | Chief Early Development | 30,000 0.045% | $38.30 | $1.15M | -15.42% | |
| 2026-09-09 | Sale | Glassman Robert | director | 8,000 0.0114% | $37.55 | $300,396 | -15.92% | |
| 2026-09-08 | Sale | Lu Peng | President | 15,000 0.0237% | $40.68 | $610,134 | -15.91% | |
| 2026-08-14 | Sale | Modig Berndt | Chief Executive Officer | 2,292 0.0033% | $34.77 | $79,686 | -4.51% | |
| 2026-07-13 | Sale | Modig Berndt | Chief Executive Officer | 2,292 0.0033% | $34.97 | $80,154 | -3.04% | |
| 2026-06-30 | Sale | Schikan Johannes Gerardus Christiaan Petrus | director | 30,712 0.0451% | $35.49 | $1.09M | -1.37% | |
| 2026-06-30 | Sale | Lesage Anne | Chief Early Development | 58,575 0.086% | $35.48 | $2.08M | -1.37% | |
| 2026-06-29 | Sale | Schikan Johannes Gerardus Christiaan Petrus | director | 2,400 0.0035% | $35.10 | $84,250 | -1.56% | |
| 2026-06-29 | Sale | Schikan Johannes Gerardus Christiaan Petrus | director | 6,888 0.01% | $35.05 | $241,447 | -1.56% | |
| 2026-06-29 | Sale | Lesage Anne | Chief Early Development | 17,597 0.0254% | $35.06 | $616,925 | -1.56% | |
| 2026-06-26 | Sale | Lu Peng | Chief Medical Officer | 14,700 0.021% | $34.00 | $499,847 | +0.75% |
| Increased Positions | 74 | +119.35% | 6M | +10.2% |
| Decreased Positions | 22 | -35.48% | 5M | -8.09% |
| New Positions | 31 | New | 2M | New |
| Sold Out Positions | 6 | Sold Out | 3M | Sold Out |
| Total Postitions | 114 | +83.87% | 59M | +2.1% |